[d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice

Regulatory Peptides

Volumn 179, Issue 1-3, 2012, Pages 33-38

  Leinung, Matthew C ^a   Grasso, Patricia ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

d Leu 4 OB3; Diabetes; Dodecyl maltoside; Exenatide; Obesity; Pramlintide acetate

Indexed keywords

DODECYLMALTOSIDE; EXENDIN 4; GLUCOSE; INSULIN; LEPTIN; PENETRATION ENHANCING AGENT; PRAMLINTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENERGY BALANCE; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DRUG COMBINATIONS; DRUG SYNERGISM; EATING; ENERGY METABOLISM; GLUCOSIDES; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISLET AMYLOID POLYPEPTIDE; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; PEPTIDE FRAGMENTS; PEPTIDES; VENOMS;

MUS;

EID: 84866271520     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.08.006     Document Type: Article

References (44)

1. Will S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes. Diabetes Care 2004, 27:1047-1053.
2. World Health Organization Obesity: prevention and managing the global epidemic. Report of a WHO consultation on obesity June 3-5 1997, Publication WHO/NUT/NCD/98.1, Geneva, Switzerland.
3. Centers for Disease Control, Prevention (CDC) Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002, MMWR. Morb Mortal Wkly Rep November 2004, 53:1066-1068. (PMID 15549021).
4. Jack L., Boseman L., Vinicor F. Aging Americans and diabetes. Geriatrics 2004, 59:14-17.
5. Lovejoy J.C. The influence of dietary fats on insulin resistance. Curr Diab Rep 2002, 2:435-440.
6. Hu F.B. Sedentary lifestyle and risk of obesity and type 2 diabetes. Lipids 2002, 38:103-108.
7. Lang I.A., Galloway T.S., Scarlett A., Henley W.E., Depledge M., Wallace R.B., Melzer D. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008, 300:1303-1310.
8. Lyssenko V., Jonsson A., Almgren P., Pulizzi N., Isomaa B., Tuomi T., Berglund G., Altshuler D., Nilsson P., Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008, 363:2220-2232.
9. Lovejoy J.C. The influence of dietary fat on insulin resistance. Curr Diab Rep 2002, 2:435-440.
10. Johnson J.A., Carstensen D., Witte D., Bowker S.L., Lipscombe L., Renchan A.G. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012, 10.1007/s00125-012-2525-1.
11. Renehen A.G., Yeh H.C., Johnson J.A., Wild S.H., Gale E.A.M., Maller H. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 2012, 10.1007/s00125-0112-2526-0.
12. Lincoff A.M., Wotski K., Nicholis S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 1 diabetes mellitus. JAMA 2007, 298:1180-1188.
13. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., Ali F., Sholley C., Worrall C., Kelman J.A. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
14. Fujita M., Yagami T., Fujio M., Tohji C., Takase K., Yamamito Y., Sawada K., Yamamori M., Okamura N. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma. Cancer Lett 2011, 312:217-227.
15. Derosa G., Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf 2012, 11:459-471.
16. Grasso P. Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs. Recent Pat Endocr Metab Immune Drug Discov 2011, 5:163-175.
17. P. Grasso, D.W. Lee, M.C. Leinung. Leptin-related, peptides. US7777388 (2004), US7186694 (2007), US7208752 (2007), US7290638 (2010), Australia772278 (2004).
18. Grasso P., Leinung M.C., Ingher S.P., Lee D.W. In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106 and 140. Endocrinology 1997, 138:1413-1418.
19. Grasso P., Leinung M.C., Lee D.W. Epitope mapping of secreted mouse leptin utilizing peripherally administered synthetic peptides. Regul Pept 1999, 84:93-100.
20. Grasso P., White D.W., Tartaglia L.A., Leinung M.C., Lee D.W. Inhibitory effects of leptin-related synthetic peptide 116-130 on food intake and body weight gain in female C57BL/6J ob/ob mice may not be mediated by peptide activation of the long isoform of the leptin receptor. Diabetes 1999, 48:2204-2209.
21. Rozhavskaya-Arena M., Lee D.W., Leinung M.C., Grasso P. Design of a synthetic leptin agonist: effects on energy balance, glucose homeostasis, and thermoregulation. Endocrinology 2000, 141:2501-2517.
22. Grasso P., Rozhavskaya-Arena M., Leinung M.C., Lee D.W. [D-Leu-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice. Regul Pept 2001, 101:123-129.
23. Maggio E.T. Intravail, highly effective intranasal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2006, 3:529-539.
24. Huang T., Cui W., Hu L., Feng K.Y., Li Y.-X., Cai Y.-D. Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. PLoS One 2009, 4:e8126.
25. Greb E. Reformulating injectables for oral delivery. Pharm Technol 2011, 35:48-56.
26. Alkyl (C10-C16) polyglycosides: exemptions from the requirement of a tolerance. Fed Regist 2005, 70:54281-54286. (40 CRF Part 180).
27. Ahsan F., Arnold J., Meezan E., Pillion D.J. Enhanced bioavailability of calcitonin formulated with alkylsaccharides following nasal and ocular administration in rats. Pharm Res 2001, 18:1742-1746.
28. Pillion D.J., Atchison J.A., Garguilo C., Wang R.S., Wang P., Meezan E. Insulin delivery in nosedrops: new formulations containing alkylglycosides. Endocrinology 1994, 135:2386-2391.
29. Ashan F., Arnold J.J., Yang T., Meesan E., Schweibert E.M., Pillion D.J. Effects of the permeability enhancers tetradecylmaltoside and dimethyl-β-17 cyclodextrin, on insulin movement across human bronchial epithelial cells. Eur J Pharm Sci 2003, 20:27-34.
30. Arnold J.J., Ahsan F., Meezan E., Pillion D.J. Nasal administration of low molecular weight heparin. J Pharm Sci 2002, 91:1707-1714.
31. Cervera A., Wajcberg E., Sriwijikamol A., Fernandez A., Triplitt P., Musi N., DeFronzo R.A., Cersosimo E. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008, 294:E846-E852.
32. Nguyen H.-N., Way S.-P., Juang J.-H., Sonaje K., Ho Y.-C., Chuang E.-Y., Hsu C.-W., Yen T.-C., Sung H.-W. The glucose lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 2011, 22:2673-2682.
33. Ryan G.J., Jobe L.J., Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2005, 26:1500-1512.
34. Novakovic Z.M., Leinung M.C., Lee D.W., Grasso P. Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels. Diabetes Obes Metab 2010, 12:532-539.
35. Waldrop M.A., Leinung M.C., Lee D.W., Grasso P. Intranasal delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin-resistant C57BLK/6-m db/db mice. Diabetes Obes Metab 2010, 12:871-875.
36. Novakovic Z.M., Leinung M.C., Lee D.W., Grasso P. Intranasal administration of mouse [D-Leu-4]-OB3, a synthetic peptide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regul Pept 2009, 154:107-111.
37. Lee D.W., Leinung M.C., Grasso P. Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal delivery. Regul Pept 2010, 160:129-132.
38. Calve M.S., Eyre D.R., Gun berg C.M. Molecular basis and clinical application of biological markers of bone formation. Endocr Rev 1996, 17:338-368.
39. Fecundate S., Martin T.J. Bone as an endocrine organ. Trends Endocrinol Metab 2009, 20:230-236.
40. Maggio E., Grasso P. Oral delivery of octreotide acetate in Intravail x improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice. Regul Pept 2011, 167:233-238.
41. Roth J.D., Roland B.L., Cole R.L., Drivakis J.L., Wryer C., Kodak J.E., Anderson C.M., Parks D.G., Baron A.D. Leptin responsiveness restored by amyl in agonist in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008, 105:7257-7262.
42. Drivakis J.L., Trek V.F., Griffin P.S., Witter C., Parks D.G., Roth J.D. Multi-hormonal weight loss combination in diet-induced obese rats: therapeutic potential of cholecystokinin?. Physiol Behav 2010, 100:187-195.
43. Moon H.-S., Chamberland J.P., Diakopoulos K.N., Fiorenza C.G., Ziemke F., Schneider B., Mantzoros C.S. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues. Diabetes Care 2011, 34:132-138.
44. Turek V.F., Trevaskis J.L., Levin B.E., Dunn-Meynell A.A., Irani B., Gu G., Wittmer C., Griffin P.S., Vu C., Parkes D.G., Roth J.D. Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 2010, 151:143-152.